When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective

Clin Pharmacol Ther. 2009 Nov;86(5):475-9. doi: 10.1038/clpt.2009.190.

Abstract

To optimize drug therapy for individuals, it is critical to understand how various intrinsic (e.g., age, gender, race, genetics, organ impairment) and extrinsic factors (e.g., diet, smoking, concomitantly administered drugs) affect drug exposure and response.(1) Up to now, it has been far easier to discover effects on exposure caused by these factors, and the US Food and Drug Administration (FDA) has published several guidance documents with recommendations on how to evaluate these factors during drug development.

MeSH terms

  • Animals
  • Drug Design*
  • Guidelines as Topic
  • Humans
  • Kidney Diseases / physiopathology*
  • Pharmaceutical Preparations / metabolism*
  • Pharmacokinetics
  • Research Design*
  • United States
  • United States Food and Drug Administration

Substances

  • Pharmaceutical Preparations